Success Metrics

Clinical Success Rate
100.0%

Based on 2 completed trials

Completion Rate
100%(2/2)
Active Trials
1(25%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_2
1
25%
Ph phase_3
2
50%
Ph phase_1
1
25%

Phase Distribution

1

Early Stage

1

Mid Stage

2

Late Stage

Phase Distribution4 total trials
Phase 1Safety & dosage
1(25.0%)
Phase 2Efficacy & side effects
1(25.0%)
Phase 3Large-scale testing
2(50.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

2 of 2 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

4

all time

Status Distribution
Active(1)
Completed(2)
Other(1)

Detailed Status

Completed2
unknown1
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
1
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 11 (25.0%)
Phase 21 (25.0%)
Phase 32 (50.0%)

Trials by Status

completed250%
unknown125%
active_not_recruiting125%

Recent Activity

1 active trials
Showing 4 of 4
completedphase_2

A Phase II Trial Evaluate the Immunogenicity and Safety Profile of HPV Vaccine

NCT05694728
completedphase_1

A Phase I Trial Evaluate the Safety and Tolerability Profile of HPV Vaccine

NCT05680454
unknownphase_3

A Phase III Trial Evaluates the Efficacy, Immunogenicity and Safety Profile of HPV Vaccine

NCT05668572
active_not_recruitingphase_3

A Study to Evaluate the Immunogenicity and Safety of HPV Vaccine in Healthy Female Participants Aged 9-26 Years in China

NCT05662020

Clinical Trials (4)

Showing 4 of 4 trials
NCT05694728Phase 2

A Phase II Trial Evaluate the Immunogenicity and Safety Profile of HPV Vaccine

Completed
NCT05680454Phase 1

A Phase I Trial Evaluate the Safety and Tolerability Profile of HPV Vaccine

Completed
NCT05668572Phase 3

A Phase III Trial Evaluates the Efficacy, Immunogenicity and Safety Profile of HPV Vaccine

Unknown
NCT05662020Phase 3

A Study to Evaluate the Immunogenicity and Safety of HPV Vaccine in Healthy Female Participants Aged 9-26 Years in China

Active Not Recruiting

All 4 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
4